Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume 22, Issue 12, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-03
DOI
10.1007/s11883-020-00893-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- (2020) Jan Borén et al. EUROPEAN HEART JOURNAL
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
- (2019) R. Preston Mason Current Atherosclerosis Reports
- Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
- (2019) Brian A. Ference et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
- (2019) Ann C. Skulas-Ray et al. CIRCULATION
- Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
- (2019) Nicholas A. Marston et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States
- (2019) Deepak L. Bhatt et al. CIRCULATION
- Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study
- (2018) Matthew Budoff et al. CLINICAL CARDIOLOGY
- Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks
- (2018) Theingi Aung et al. JAMA Cardiology
- Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
- (2018) Stephen J. Nicholls et al. CLINICAL CARDIOLOGY
- Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
- (2018) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
- (2017) Brian A. Ference et al. EUROPEAN HEART JOURNAL
- Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study
- (2017) Kazumasa Nosaka et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease
- (2017) Amit V. Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
- (2017) Tetsu Watanabe et al. Journal of Cardiology
- Hypertriglyceridaemia and risk of coronary artery disease
- (2017) Željko Reiner Nature Reviews Cardiology
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
- (2017) John W. Eikelboom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
- (2017) Frederick E. Dewey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Total Cholesterol, Triglycerides, and Low-Density Lipoprotein in US Adults, 1999-2014
- (2017) Asher Rosinger et al. JAMA Cardiology
- Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
- (2016) Matthew Budoff AMERICAN JOURNAL OF CARDIOLOGY
- Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease
- (2016) Børge G. Nordestgaard CIRCULATION RESEARCH
- Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis
- (2016) Kiran Musunuru et al. CIRCULATION RESEARCH
- Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis
- (2015) Kenneth M. Borow et al. ATHEROSCLEROSIS
- Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
- (2014) M. Thomsen et al. CLINICAL CHEMISTRY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
- (2013) Anette Varbo et al. CIRCULATION
- Relationship of Lipoproteins to Cardiovascular Events
- (2013) John R. Guyton et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Common variants associated with plasma triglycerides and risk for coronary artery disease
- (2013) Ron Do et al. NATURE GENETICS
- Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
- (2012) Christie M. Ballantyne et al. AMERICAN JOURNAL OF CARDIOLOGY
- Highly Purified Eicosapentaenoic Acid Increases Interleukin-10 Levels of Peripheral Blood Monocytes in Obese Patients With Dyslipidemia
- (2012) N. Satoh-Asahara et al. DIABETES CARE
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Omega-3 Fatty Acids and Cardiovascular Disease
- (2011) Dariush Mozaffarian et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Eicosapentaenoic acid (EPA) from highly concentrated n−3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability
- (2010) Abbie L. Cawood et al. ATHEROSCLEROSIS
- Combination Lipid Therapy in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Incremental Effects of Eicosapentaenoic Acid on Cardiovascular Events in Statin-Treated Patients With Coronary Artery Disease
- (2009) Masunori Matsuzaki et al. CIRCULATION JOURNAL
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started